Cancer Biopsy

Cancer Biopsy Market Outlook

The global cancer biopsy market is projected to reach approximately USD 12.5 billion by the year 2025, growing at a compound annual growth rate (CAGR) of around 8.2% from 2025 to 2035. This growth can be attributed to an increasing prevalence of cancer across the globe, advancements in biopsy technologies, and a growing emphasis on early and accurate diagnosis of various cancer types. The rising geriatric population, which is more susceptible to various forms of cancer, further drives the demand. Additionally, the growing awareness about the importance of regular health check-ups and screenings has led to increased patient visits to healthcare facilities, thereby propelling the market forward. Enhanced funding from government and private sectors for cancer research is also expected to bolster market growth significantly.

Growth Factor of the Market

Several factors contribute to the robust growth of the cancer biopsy market. One significant factor is the increase in the global incidence of cancer, which necessitates improved diagnostic and therapeutic methods. Furthermore, the introduction of innovative biopsy techniques, such as liquid biopsy, has further enhanced the accuracy and efficiency of cancer detection, making these methods increasingly popular among healthcare providers and patients alike. The integration of advanced imaging technologies and minimally invasive procedures has made biopsies safer and more effective, thus boosting patient acceptance. Additionally, the rise in healthcare expenditure and the development of novel biomarkers for cancer diagnosis are creating more opportunities for market expansion. The increased focus on personalized medicine is also influencing the growth of the cancer biopsy market, as tailored treatment plans require precise and accurate diagnostic methods.

Key Highlights of the Market

• The market is expected to exhibit a CAGR of 8.2% from 2025 to 2035.
• Liquid biopsy is emerging as a groundbreaking technique, offering non-invasive cancer detection.
• North America holds a significant share of the market, driven by advanced healthcare infrastructure.
• Breast and lung cancers are the leading applications for biopsy procedures worldwide.
• Technological advancements in imaging and minimally invasive techniques are changing the landscape of cancer diagnosis.

By Product Type

Needle Biopsy:

Needle biopsy is one of the most commonly used techniques in the cancer biopsy market. It involves the extraction of tissue or fluid samples using a thin needle, which can be done using either a fine-needle aspiration or a core needle. The procedure is minimally invasive and carries a lower risk of complications, making it a preferred choice among healthcare providers and patients. Needle biopsies are particularly useful for diagnosing tumors in locations that are hard to access, such as the lungs or lymph nodes. The rising number of diagnostic imaging procedures that guide needle biopsy is further driving the growth of this segment. This method allows for real-time visualization, improving the accuracy of the sample collection, and consequently the diagnosis.

Surgical Biopsy:

Surgical biopsy involves the surgical removal of either a part of or an entire tumor for diagnostic evaluation. This type of biopsy is generally considered when needle biopsy does not provide enough tissue samples or when the tumor is large. Surgical biopsies can be open or minimally invasive, and they allow for thorough pathological evaluation, which is crucial for accurate diagnosis and staging of cancer. This segment is experiencing growth as more patients are being diagnosed with late-stage cancers that require more extensive procedures. The technological advancements in surgical techniques, such as robotic surgery, are also enhancing the demand for surgical biopsy procedures, as they offer improved precision and reduced recovery times for patients.

Liquid Biopsy:

Liquid biopsy represents a revolutionary approach in cancer diagnostics, involving the analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), or exosomes in a non-invasive manner. This method is gaining traction due to its ability to provide crucial information about the tumor without the need for traditional tissue sampling. Liquid biopsies can enable early detection and monitoring of treatment response, which is vital for personalized cancer therapy. As such, the liquid biopsy segment is projected to grow significantly in the coming years, driven by technological advancements and an increasing number of clinical studies validating its efficacy. The ability to monitor cancer progression and treatment efficacy in real-time adds a compelling advantage to this biopsy type.

Bone Marrow Biopsy:

Bone marrow biopsy is a specialized procedure used primarily to diagnose blood cancers such as leukemia and lymphoma. It involves the extraction of bone marrow tissue, typically from the hip bone, for laboratory analysis. This biopsy type helps in assessing the presence of abnormal cells and evaluating the overall health of the bone marrow. The segment is expected to witness steady growth as the incidence of blood-related cancers continues to rise globally. Furthermore, advancements in imaging techniques and needle designs have improved the safety and comfort levels associated with bone marrow biopsies, making it a more viable option for patients. Enhanced awareness among healthcare providers regarding the importance of early diagnosis in hematological malignancies will also contribute to the growth of this segment.

Endoscopic Biopsy:

Endoscopic biopsy is performed during an endoscopic procedure where a flexible tube with a camera is inserted into the body to visualize and collect tissue samples from various organs, including the gastrointestinal and respiratory tracts. This type of biopsy allows for direct visualization of lesions, which increases the accuracy of sample collection. The demand for endoscopic biopsies is on the rise due to the increasing prevalence of cancers in the gastrointestinal tract, along with the growing adoption of minimally invasive surgical techniques. The development of advanced endoscopic devices and tools is also enhancing the precision of this biopsy type. As awareness about the importance of early detection of gastrointestinal cancers increases, the endoscopic biopsy segment is likely to expand further.

By Application

Breast Cancer:

Breast cancer remains one of the most prevalent types of cancer globally, prompting a significant focus on early detection and effective treatment strategies. The application of biopsy in breast cancer diagnosis is critical, as it provides essential information regarding the tumor type and stage, which is vital for determining the appropriate treatment plan. Advances in imaging techniques, such as mammography and MRI, have improved the accuracy of breast biopsies, thereby enhancing patient outcomes. With the rising incidence of breast cancer, particularly among women, the demand for breast cancer biopsy procedures continues to grow, driving the overall market forward.

Lung Cancer:

Lung cancer is another major application area for biopsies, with an increasing number of diagnoses occurring each year. Lung biopsies can be performed using various techniques, including needle biopsy and bronchoscopy, to collect samples from lung tissues or masses. The rising incidence of lung cancer, coupled with a growing emphasis on early diagnosis, has propelled the demand for lung biopsy procedures. Additionally, advancements in imaging technologies that facilitate guided biopsies have significantly improved the rate of successful diagnoses. As smoking rates continue to decline and awareness about lung cancer increases, the demand for effective diagnostic methods such as biopsies will remain crucial.

Prostate Cancer:

Prostate cancer is one of the most common types of cancer affecting men, and biopsy plays a vital role in its diagnosis and management. The standard approach to diagnose prostate cancer is through a transrectal ultrasound-guided biopsy, which enables the collection of tissue samples from the prostate gland. The rising awareness regarding prostate cancer screening and the introduction of advanced imaging techniques are contributing to the increased adoption of prostate biopsies. Furthermore, as more men seek regular health check-ups and screenings, there will be an uptick in prostate cancer diagnoses, thus fostering the growth of this segment in the cancer biopsy market.

Colorectal Cancer:

Colorectal cancer is the third most commonly diagnosed cancer worldwide, and biopsies are critical for accurate diagnosis and staging. Procedures such as colonoscopy allow for direct visualization and sampling of suspicious lesions in the colon. The growing prevalence of colorectal cancer, alongside increasing awareness about the importance of screening, is driving the demand for colorectal biopsies. Moreover, advancements in endoscopic technologies are enhancing the accuracy and safety of these procedures, contributing to the growth of this specific application in the cancer biopsy market. The implementation of screening guidelines and the rising focus on preventive healthcare measures are also expected to drive this segment considerably.

Blood Cancer:

Blood cancers, including leukemia, lymphoma, and multiple myeloma, necessitate specialized diagnostic approaches, with bone marrow biopsies being a primary method for diagnosis and monitoring. As the incidence of blood cancers continues to rise, the demand for effective biopsy techniques has surged. Blood cancer biopsies are crucial for identifying the type and stage of cancer, which directs treatment decisions. The growing awareness and education surrounding blood cancers are prompting more patients to seek medical attention, resulting in a higher number of biopsy procedures being performed. As research efforts continue to focus on innovative treatment options for blood cancers, the importance of accurate diagnostic methods such as biopsies will remain paramount in driving this segment forward.

By Distribution Channel

Hospitals:

Hospitals remain the primary distribution channel for cancer biopsies, owing to their comprehensive healthcare services and expert medical teams. Many hospitals are equipped with advanced diagnostic imaging technologies and surgical facilities that facilitate the performance of various biopsy types, making them the go-to option for patients. The growing prevalence of cancer and the increasing patient load in hospitals are driving the demand for biopsy procedures within this channel. Furthermore, collaborations and partnerships between hospitals and diagnostic laboratories are enhancing the efficiency of biopsy services, thus contributing to the growth of this segment.

Specialty Clinics:

Specialty clinics that focus on oncology and diagnostic services are witnessing significant growth as they provide tailored care and advanced diagnostic techniques for cancer patients. These clinics are often equipped with cutting-edge technology that allows for precise and efficient biopsy procedures. The convenience and personalized care offered by specialty clinics are appealing to patients seeking quicker results and specialized expertise. As patients increasingly seek second opinions and specialized diagnostic services, the demand for cancer biopsy procedures in specialty clinics is expected to rise significantly.

Diagnostic Laboratories:

Diagnostic laboratories play a crucial role in the cancer biopsy market, particularly in the analysis and evaluation of biopsy samples. These laboratories often collaborate with hospitals and specialty clinics to provide accurate and timely diagnostic results. The increasing emphasis on personalized medicine is driving demand for advanced diagnostic tests, including genetic and molecular analyses, which are often performed in laboratories following a biopsy. With ongoing advancements in laboratory technologies and processes, diagnostic laboratories are positioned to significantly contribute to the growth of the cancer biopsy market.

Research Institutes:

Research institutes are essential for advancing the understanding of cancer and developing innovative diagnostic techniques. Many research institutes focus on studying the efficacy of new biopsy methods and are involved in clinical trials that aim to validate these techniques. The collaboration between research institutions and healthcare providers is critical for improving biopsy technologies and procedures, thereby enhancing patient care. The funding and support for cancer research initiatives are also expected to boost the demand for cancer biopsy procedures within research institutes, as they seek to contribute to the overall body of knowledge in oncology.

Others:

Other distribution channels for cancer biopsies may include mobile health units and telemedicine services, which are gaining traction in response to the growing demand for accessible healthcare solutions. Mobile health units can offer preliminary screening and diagnostic services, including biopsies, in remote or underserved areas. Telemedicine services allow for consultations and follow-ups, enabling patients to access diagnostic services without the need for extensive travel. As these alternative distribution channels become more popular, the overall cancer biopsy market is likely to expand, providing more patients with access to necessary diagnostic services.

By Technique

Fine-needle Aspiration Biopsy:

Fine-needle aspiration biopsy (FNAB) is a minimally invasive technique where a thin needle is used to extract samples from a tumor or suspicious area. This method is particularly effective for palpable masses and lymph nodes and is preferred for its simplicity and low complication rates. The FNAB technique is rapidly gaining popularity due to its efficiency and the quick turnaround time for results. As patients seek less invasive options for biopsy procedures, the demand for FNAB is expected to grow significantly, driven by the rising incidences of various cancers.

Core Needle Biopsy:

Core needle biopsy (CNB) involves using a larger, hollow needle to remove a core of tissue from a tumor. This technique allows for the collection of larger and more intact samples, which are essential for proper pathological evaluation. CNB is commonly used for breast and prostate cancer diagnoses and is known for its accuracy in determining cancer types and grades. The growing awareness of breast cancer screening guidelines and advancements in imaging technologies that guide these biopsies contribute to the increasing adoption of core needle biopsies in the market.

Vacuum-assisted Biopsy:

Vacuum-assisted biopsy (VAB) is an advanced technique that allows for the removal of multiple tissue samples during one procedure, using a vacuum-powered device. This method is particularly useful for larger or complex tumors, as it provides higher yield and minimizes the number of necessary procedures. The VAB technique is increasingly favored in breast cancer diagnosis due to its ability to provide comprehensive tissue sampling while maintaining patient comfort. As the demand for efficient and accurate diagnostic methods rises, the vacuum-assisted biopsy segment is expected to experience substantial growth.

Image-guided Biopsy:

Image-guided biopsy utilizes imaging techniques such as ultrasound, CT, or MRI to precisely locate and sample tissues from tumors. This method enhances the accuracy of biopsy procedures, reducing the likelihood of sampling errors and improving diagnostic yield. Image-guided biopsies are particularly beneficial for lesions that are challenging to access, such as those deep within the body. With the increasing availability of advanced imaging technologies and the growing demand for minimally invasive diagnostic techniques, the image-guided biopsy segment is projected to witness significant growth in the coming years.

Liquid Biopsy:

Liquid biopsy is a non-invasive technique that analyzes circulating tumor cells or cell-free DNA in blood samples, providing insights into tumor characteristics and treatment responses. This method has gained considerable attention due to its potential for early cancer detection and monitoring. Liquid biopsy is particularly advantageous as it eliminates the need for invasive procedures and offers a dynamic approach to assessing tumor behavior over time. As research and clinical applications of liquid biopsies expand, this segment is expected to grow substantially, driven by the increasing focus on personalized cancer therapies and real-time monitoring.

By Region

The North American region holds a dominant position in the cancer biopsy market, accounting for approximately 40% of the global market share. The high prevalence of cancer, coupled with advanced healthcare infrastructure and significant investment in cancer research, propels the market in this region. The United States is a key contributor, with numerous leading medical centers and a well-established framework for cancer treatment and diagnostics. The CAGR for this region is estimated at around 8.5%, reflecting the ongoing advancements in biopsy technologies and the increasing emphasis on early detection and personalized medicine.

In Europe, the cancer biopsy market is also experiencing steady growth, driven by factors such as the rising incidence of cancer and the growing emphasis on preventive healthcare. The market share for Europe is estimated to be around 30%, with countries like Germany, the UK, and France leading the way in terms of advanced healthcare facilities and research initiatives. The increasing government support for cancer research and the establishment of cancer screening programs are further contributing to the growth of the cancer biopsy market in this region. The Asia Pacific region is gradually emerging as a significant player in this market, expected to witness a CAGR of over 9% during the forecast period, driven by the rising healthcare expenditure and increasing awareness about cancer diagnostics.

Opportunities

The cancer biopsy market presents numerous opportunities for growth and innovation in the coming years. One of the most significant opportunities lies within the development and adoption of advanced technologies, such as digital pathology and artificial intelligence, which can enhance the accuracy and efficiency of biopsy diagnostics. The integration of AI algorithms with diagnostic imaging can aid pathologists in identifying cancerous tissues more effectively and streamlining the overall diagnostic process. Furthermore, the emergence of novel biomarkers and companion diagnostics can facilitate personalized cancer treatment, enabling more targeted therapies tailored to individual patient profiles. Such advancements not only improve patient outcomes but also increase the efficiency of healthcare systems, making this an attractive area for investment and development.

Moreover, the increasing focus on preventive healthcare and early diagnosis provides a fertile ground for growth in the cancer biopsy market. As governments and healthcare organizations worldwide implement screening programs to detect cancer at earlier stages, the demand for biopsy procedures is expected to rise significantly. Additionally, the growing trend of telemedicine services can enhance patient access to diagnostic services, especially in remote or underserved areas, creating further opportunities for market expansion. The continuous push for research and development in oncology is likely to unveil new diagnostic tools and techniques, ensuring that the cancer biopsy market remains dynamic and adaptable to changing patient needs.

Threats

While the cancer biopsy market presents numerous growth opportunities, there are inherent threats that could hinder its progress. One of the primary challenges is the rising costs associated with advanced diagnostic procedures and technologies, which may limit accessibility for certain patient populations. The high expense of innovative biopsy techniques, along with the costs of associated imaging technologies, may pose financial barriers that prevent patients from receiving timely access to necessary diagnostic services. Furthermore, the increasing prevalence of stringent regulatory requirements and the need for compliance with various health standards may complicate the approval processes for new biopsy technologies, leading to delays in market entry and potential lost revenue.

Another significant threat to the cancer biopsy market is the competition from alternative diagnostic methods, such as liquid biopsies and non-invasive imaging techniques. As these alternatives gain popularity, they may overshadow traditional biopsy methods, leading to a reduction in demand for conventional procedures. Additionally, the prevalence of misdiagnosis or inconclusive results from biopsy procedures can undermine patient confidence and trust in these diagnostic methods, potentially discouraging patients from opting for biopsies altogether. Addressing these concerns and maintaining a focus on improving diagnostic accuracy and patient experience will be crucial for the cancer biopsy market to thrive in the face of competition and evolving healthcare demands.

Competitor Outlook

• Roche Holding AG
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• GE Healthcare
• Siemens Healthineers
• Abbott Laboratories
• Merck KGaA
• Cardinal Health, Inc.
• Philips Healthcare
• Agilent Technologies, Inc.
• Sysmex Corporation
• NeoGenomics, Inc.
• Exact Sciences Corporation
• PathAI

The competitive landscape of the cancer biopsy market is marked by a diverse range of players, from established pharmaceutical and diagnostic companies to specialized biotechnology firms. Major players such as Roche Holding AG and Thermo Fisher Scientific Inc. are at the forefront of innovation, continuously developing advanced diagnostic tools and technologies to enhance precision and patient outcomes. These companies leverage their extensive research capabilities and established distribution networks to maintain a competitive edge in the market. In addition, they often engage in strategic collaborations and partnerships with healthcare providers and research institutions to expand their market reach and enhance their product offerings.

Companies like Illumina, Inc. and F. Hoffmann-La Roche Ltd. are notable for their cutting-edge advancements in genetic testing and precision medicine, making significant contributions to the field of cancer diagnostics. Their focus on developing next-generation sequencing and liquid biopsy technologies is expected to play a critical role in shaping the future of cancer diagnosis. Furthermore, major players such as GE Healthcare and Siemens Healthineers are investing heavily in imaging technologies that complement biopsy procedures, thereby enhancing the overall diagnostic process. As the market continues to evolve, these companies are likely to drive significant advancements in cancer biopsy methodologies and technologies.

In addition to established companies, several emerging players, such as NeoGenomics, Inc. and Exact Sciences Corporation, are gaining prominence in the cancer biopsy space. These companies specialize in providing innovative solutions for cancer diagnostics and are at the forefront of research and development in areas such as liquid biopsy and molecular testing. Their agility and focus on niche markets enable them to compete effectively with larger players while contributing to the diversification of the cancer biopsy market. The dynamic nature of the competitive landscape underscores the need for continuous innovation and adaptation to changing market trends, ensuring that all players remain relevant and responsive to the evolving needs of patients and healthcare providers.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 PathAI
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Merck KGaA
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 GE Healthcare
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Illumina, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Roche Holding AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 NeoGenomics, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Philips Healthcare
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Sysmex Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Abbott Laboratories
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Siemens Healthineers
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Cardinal Health, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 F. Hoffmann-La Roche Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Agilent Technologies, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Exact Sciences Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Thermo Fisher Scientific Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Cancer Biopsy Market, By Technique
    • 6.1.1 Fine-needle Aspiration Biopsy
    • 6.1.2 Core Needle Biopsy
    • 6.1.3 Vacuum-assisted Biopsy
    • 6.1.4 Image-guided Biopsy
    • 6.1.5 Liquid Biopsy
  • 6.2 Cancer Biopsy Market, By Application
    • 6.2.1 Breast Cancer
    • 6.2.2 Lung Cancer
    • 6.2.3 Prostate Cancer
    • 6.2.4 Colorectal Cancer
    • 6.2.5 Blood Cancer
  • 6.3 Cancer Biopsy Market, By Product Type
    • 6.3.1 Needle Biopsy
    • 6.3.2 Surgical Biopsy
    • 6.3.3 Liquid Biopsy
    • 6.3.4 Bone Marrow Biopsy
    • 6.3.5 Endoscopic Biopsy
  • 6.4 Cancer Biopsy Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Specialty Clinics
    • 6.4.3 Diagnostic Laboratories
    • 6.4.4 Research Institutes
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Cancer Biopsy Market by Region
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Cancer Biopsy market is categorized based on

By Product Type

• Needle Biopsy
• Surgical Biopsy
• Liquid Biopsy
• Bone Marrow Biopsy
• Endoscopic Biopsy

By Application

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Colorectal Cancer
• Blood Cancer

By Distribution Channel

• Hospitals
• Specialty Clinics
• Diagnostic Laboratories
• Research Institutes
• Others

By Technique

• Fine-needle Aspiration Biopsy
• Core Needle Biopsy
• Vacuum-assisted Biopsy
• Image-guided Biopsy
• Liquid Biopsy

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Roche Holding AG
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• GE Healthcare
• Siemens Healthineers
• Abbott Laboratories
• Merck KGaA
• Cardinal Health, Inc.
• Philips Healthcare
• Agilent Technologies, Inc.
• Sysmex Corporation
• NeoGenomics, Inc.
• Exact Sciences Corporation
• PathAI